Washington Health Institute

What it reported doing in 2024

Clinical trials: whi strives to bring the cutting edge of drug development and advanced therapies to our communities through participation in clinical trials. Whi has partnered to conduct clinical research trials with major pharmaceutical companies such as gilead sciences, gsk, viiv, moderna, and pfizer. It is the hope of whi that by conducting clinical research in our under-represented and under-served communities, we can diversify the face of medicine and pharmaceutical-based care and bring change for the betterment of all. This program has also helped bring new technologies to the organization including the addition of radiologic imaging and fibroscans, a non-invasive liver cirrhosis assessment tool.eis program: the early intervention services (eis) team at Washington health institute provides targeted outreach to residents of Washington, dc and prince georges county, Maryland who are at increased risk for HIV infection. Eis provides rapid HIV testing, HIV and sexual health risk-assessment counseling, and safer-sex materials (including prep, pep and safe sex supplies) to those seeking HIV-prevention services. Additionally, eis helps connect existing whi patients to services and resources as part of its non-medical case management team to help improve the quality of life and holistic health of patients. From july 1, 2024, to june 30, 2025, eis served 690 individuals.syndemic program: whi's syndemic team provides targeted HIV, viral hepatitis, and sexually transmitted infections testing to residents of Washington, dc via the whi mobile unit. The syndemic program refers to a public health strategy that addresses the interconnectedness of multiple health conditions, substance use disorders, and mental health issues. From july 1, 2024, to june 30, 2025, the syndemic team procured a whi mobile unit, which served 405 unique individuals.the dc cohort grant: led by the george Washington university milken institute school of public health, the dc cohort is a longitudinal research project that collects clinical data from approximately 19,000 consenting people with HIV receiving care at fifteen HIV clinics in the district of columbia. The dc cohort is sponsored by the national institute of health (nih) and the national institute of allergy and infectious diseases (niaid). The primary project goal is to improve the quality of care and treatment of people with HIV receiving care at large clinics in the district of columbia. Under the dc cohort study, there are smaller projects, including the molecular epidemiology sub-study, covid-19 sub-study; patient reported outcomes sub-study, aging sub-study and more. The dc cohort contributes to the research of emerging issues in the prevention, treatment, and long-term effects of people with HIV. The project's scientific objectives are to contribute to the understanding of the experiences and medical care of people with HIV or at risk of contracting HIV.other programs: whi is focused on other key areas of treatment that take a holistic approach to health and patient well-being. Our programs include infectious disease care, primary care for our patients, telehealth visits, prevention of HIV and sti's, on-site phlebotomy services, a mobile unit, peer support groups for patients, and a wellness program.

Financial Efficiency

• Mission deployment rate: 86.2%; rating input score 86
• Program expense ratio: 94.6%; rating input score 95
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 62nd percentile among comparable filings
• Pay-setting controls: 1 of 6 controls in place; rating input score 17
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Missing
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 66th percentile among comparable filings
• Governance controls: 5 of 9 controls in place; rating input score 56
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Fail
  • Document-retention policy: Fail
  • CEO compensation review process: Fail
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 8.7%; rating input score 64; 64th percentile among comparable filings
• Total-asset coverage ratio: 0.35; rating input score 10; 10th percentile among comparable filings
• Liabilities to assets ratio: 0.43; rating input score 34; 34th percentile among comparable filings
• Officer compensation ratio: 7.4%; rating input score 33; 33rd percentile among comparable filings

Growth

• Program expense growth: 36.4% per year; rating input score 100; 97th percentile among comparable filings
• Revenue growth: 36.4% per year; rating input score 100; 97th percentile among comparable filings
• Asset growth: 39.7% per year; rating input score 100; 98th percentile among comparable filings